Minovia Receives $350,000 Grant for Blood-Based Biomarker Research
Minovia Therapeutics Secures Funding, Reinforcing the Rise of Mitochondrial Medicine Minovia Therapeutics, a clinical-stage biotech company focused on mitochondrial...
Jon Napitupulu
Quell Therapeutics Forms World-Class Scientific Advisory Board
Quell Therapeutics has established a Scientific Advisory Board to steer its engineered T‑regulatory cell therapy portfolio, spanning transplantation and...
Idorsia’s Tryvio: First FDA-Approved Endothelin Receptor Antagonist for Hypertension
Idorsia has released an on-demand investor briefing positioning Tryvio (aprocitentan) as a foundational add-on for difficult-to-control hypertension, with a...
Rhythm Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhythm Pharmaceuticals will put its story in front of Wall Street next month, with its chair, president, and CEO...
Comirnaty Approved for Adults 65+ and High-Risk Individuals 5-64
FDA has approved Pfizer and BioNTech’s LP.8.1-adapted monovalent Comirnaty for adults 65 and older and for individuals 5 to...
Moonlake Reports Phase 3 Hidradenitis Suppurativa Results
Moonlake Immunotherapeutics reported 16-week results from its two identically designed Phase 3 VELA trials of sonelokimab in moderate-to-severe hidradenitis...
Leqembi IV Maintenance Dosing Approved in China for Alzheimer’s
China’s National Medical Products Administration has approved once-every-four-weeks intravenous maintenance dosing for Leqembi (lecanemab), following 18 months of 10...
MoonLake Reports VELA Phase 3 HS Results with Sonelokimab
MoonLake Immunotherapeutics reported week 16 readouts from its two pivotal Phase 3 trials in hidradenitis suppurativa. In VELA-1, sonelokimab...
Profusa and Medical University of Graz Announce Collaboration
Profusa has entered a commercial and clinical collaboration with Prof. Dr. Marianne Brodmann at the Medical University of Graz,...
Onconetix’s New Focus: Secures Financing, Ends Ocuvex Deal
Onconetix has closed a $12.9 million private placement comprising Series D convertible preferred stock and warrants, using the raise...